Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06660654 · ClinicalTrials.gov registry record · Phase 2

A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)

A Phase 2 study of Advanced Solid Tumor and Metastatic Solid Tumors, sponsored by Daiichi Sankyo.

Recruiting
Registry status
Phase 2
Development phase
200
Enrollment target
20
Study locations

NCT06660654 is a Phase 2 study of Advanced Solid Tumor and Metastatic Solid Tumors that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 200 participants, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target. The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06660654, a Phase 2 study of Advanced Solid Tumor and Metastatic Solid Tumors, is actively recruiting participants, sponsored by Daiichi Sankyo.

RECRUITING
Registry status
Phase 2
Development phase
200 participants
Enrollment target
20
Study locations

Study Summary

This pan-tumor trial is designed as a signal-seeking trial to assess efficacy and safety of raludotatug deruxtecan (R-DXd) monotherapy in locally advanced or metastatic solid tumors with various cadherin-6 (CDH6) expression levels, including gynecological cancers (endometrial cancer, cervical cancer, and non-high-grade serous ovarian cancer) and genitourinary cancers (urothelial cancer and clear cell renal cell carcinoma \[ccRCC\]).

Conditions Studied

Advanced Solid Tumor Metastatic Solid Tumors

Interventions

  • DRUG Raludotatug deruxtecan

Study Locations (20)

Other

  • UZ Leuven Gynaec onco - Leuven
  • ZAS Sint-Augustinus - Wilrijk
  • Hunan Cancer Hospital - Changsha
  • Shanghai Cancer center - Shanghai
  • Herlev og Gentofte Hosp - Copenhagen
  • François Baclesse Center - Caen
  • Centre Georges-François Leclerc - Dijon
  • Centre Oscar Lambret - Lille
  • Centre Leon Berard - Lyon
  • Grp Hsp Diac Croix Saint Simon - Paris
  • Cario - Centre Armoricain de Radiothérapie, Imagerie Médicale Et Oncologie - Plérin
  • Ico - Site René Gauducheau - Saint-Herblain

New York

  • Women's Cancer Care Associates - Albany
  • Memorial Sloan-Kettering Cancer Center - New York
  • Clinical Research Alliance - Westbury

Georgia

  • Northside Hospital - Marietta

Michigan

  • University of Michigan Comprehensive Cancer Center Michigan Medicine - Ann Arbor

New Jersey

  • Astera Cancer Care - East Brunswick

Tennessee

  • West Cancer Center and Research Institute - Germantown

Texas

  • The University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2025-01-06
Est. Completion 2027-09-30
Phase Phase 2

Sponsor

Daiichi Sankyo

236 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06660654

The ClinicalTrials.gov registry entry for NCT06660654 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Raludotatug deruxtecan is the first listed.

NCT06660654 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, New York, Georgia.

Frequently Asked Questions

What is clinical trial NCT06660654 about?

NCT06660654 is a clinical study titled "A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)". This pan-tumor trial is designed as a signal-seeking trial to assess efficacy and safety of raludotatug deruxtecan (R-DXd) monotherapy in locally advanced or metastatic solid tumors with various cadherin-6 (CDH6) expression levels, including gynecological cancers (endometrial cancer, cervical cancer...

What is the current status of trial NCT06660654?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-01-06. Estimated completion is 2027-09-30.

What conditions does trial NCT06660654 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Metastatic Solid Tumors.

What interventions are being tested in trial NCT06660654?

The interventions under investigation include: Raludotatug deruxtecan (DRUG).

Who is sponsoring clinical trial NCT06660654?

This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06660654 being conducted?

This trial has 20 study locations across Georgia, Michigan, New Jersey, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Metastatic Solid Tumors

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.